Form 4: Solen Therapeutics Director Matthew Pauls Reports Stock Transactions
SEC Form 4 Filing
Director Matthew Pauls of Soleno Therapeutics reports the acquisition and disposal of common stock and derivative securities.
Summary
- On March 28, 2025, Matthew Pauls, a director of Soleno Therapeutics Inc., reported transactions involving the company's stock.
- Pauls acquired 5,937 shares of common stock at $4.6 per share and disposed of 5,937 shares at a weighted average price of $71.5508.
- Following these transactions, Pauls directly owns 12,437 shares of common stock and 9,063 derivative securities.
- The derivative securities are employee stock options with an exercise price of $46.31, expiring on August 15, 2033.
- The reported transactions also involved the vesting of employee stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders (directors, officers, and 10% owners) of publicly traded companies, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into their perspective on the company's value and prospects.
Key Dates
| Date | Description |
|---|---|
| 09/15/2023 | One forty-eighth (1/48th) of the shares subject to the Option shall vest on September 15, 2023 and each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date. |
| 03/28/2025 | Date of earliest transaction: Acquisition and disposal of common stock and vesting of employee stock options. |
| 03/31/2025 | Date of signature on the Form 4 filing. |
| 08/15/2033 | Expiration date of employee stock options. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Director, SLNO, Solen Therapeutics, Matthew Pauls, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.